News Agency
The Times

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

  • Written by PR Newswire
  • The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication[1]
  • The European...

Read more: Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in...

Google Ads Agency Sydney: How to Generate More Qualified Leads With Paid Search

When someone searches Google for a service they need immediately, appearing at the right moment can be extremely valuable. Unlike many traditional marketing channels, paid search can place a business in front of people who are already researching a product... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion